Neurocrine Biosciences (NBIX) Receivables - Net (2010 - 2026)

Neurocrine Biosciences has reported Receivables - Net for 17 years, with the latest figure at $768.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 48.86% year-over-year to $768.1 million; the trailing twelve-month figure through Mar 2026 stood at $768.1 million (up 48.86% YoY), and the FY2025 full-year result was $686.8 million, up 43.35% from the prior year.
• Receivables - Net for Q1 2026 stood at $768.1 million, up from $686.8 million in the prior quarter.
• The five-year high for Receivables - Net was $768.1 million in Q1 2026, with the low at $263.5 million in Q1 2022.
• Historically, Receivables - Net has averaged $470.8 million across 5 years, with a median of $450.7 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net jumped 88.68% — and 2024, when it grew 9.06%.
• Neurocrine Biosciences' Receivables - Net stood at $350.0 million in 2022, then grew by 25.51% to $439.3 million in 2023, then increased by 9.06% to $479.1 million in 2024, then jumped by 43.35% to $686.8 million in 2025, then advanced by 11.84% to $768.1 million in 2026.
• The last three Receivables - Net figures came in at $768.1 million (Q1 2026), $686.8 million (Q4 2025), and $728.0 million (Q3 2025), per Business Quant data.